{"id":"W4408405657","doi":"10.1001/jama.2025.1132","title":"Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma","year":2025,"lang":"en","type":"letter","venue":"JAMA","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Nasopharyngeal carcinoma; Internal medicine; Oncology; Clinical endpoint; Adverse effect; Chemoradiotherapy; Adjuvant therapy; Randomized controlled trial; Adjuvant; Survival rate; Surgery; Confidence interval; Radiation therapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007894799,0.00043038,0.001146751,0.0001833889,0.0001401394,0.00003037515,0.0001671322,0.0006469525,0.00008440891],"category_scores_gemma":[0.00008907392,0.0003090135,0.0002367498,0.0001671001,0.0000948697,0.00003802333,0.00007150136,0.001314903,0.00002572383],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000240464,"about_ca_system_score_gemma":0.0007482253,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002020163,"about_ca_topic_score_gemma":0.00005046829,"domain_scores_codex":[0.9980649,0.00002668196,0.0003167087,0.0006007609,0.0004004557,0.0005905102],"domain_scores_gemma":[0.9987701,0.000221548,0.0001116571,0.0005219284,0.0002837256,0.00009108416],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007446478,0.0000305113,0.0005728294,0.001950153,0.0003508004,0.001297576,0.0001881291,1.477065e-7,0.00002167677,0.000009699926,0.9822917,0.01254216],"study_design_scores_gemma":[0.006614919,0.001261913,0.003958642,0.001164317,0.0007449235,0.0001183614,0.00003840889,0.00002708945,0.0004910778,0.0000224597,0.9852321,0.0003257689],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.004377481,0.005166941,0.0000528464,0.9664322,0.0008221331,0.001390627,0.0003943858,0.0001291267,0.02123425],"genre_scores_gemma":[0.01496256,0.0002256227,0.0008323196,0.8995675,0.01375537,0.0006794572,0.0007190529,0.0001079918,0.06915005],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.06686464,"threshold_uncertainty_score":0.9999362,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01954001674613063,"score_gpt":0.2770147039498509,"score_spread":0.2574746872037203,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}